Tag: Developmental Therapeutics and Immuno-Oncology

Dr. Nageatte Ibrahim helped guide the clinical development of Keytruda, one of the most consequential immuno-oncology therapies SCOTTSDALE, Ariz. — May 12, 2026 — Nageatte Ibrahim, M.D., an internationally recognized oncology drug development leader and immuno-oncology expert, has been appointed as Research Director of Developmental Therapeutics and Immuno-Oncology for HonorHealth Research Institute. Starting May 18,…